Business Wire

European Tourists to the UK Could Drop by a Third Following Brexit


A vote to leave the European Union this month could cost the UK’s tourism industry as much as £4.1 billion a year in international tourist spending alone. According to new research* published today by global travel deals publisher Travelzoo (NASDAQ: TZOO), a third of travellers from Germany, Italy and Spain – and a quarter from France – say they would be less inclined to travel to the UK in the event of a Leave vote. Four in 10 respondents from EU countries also worry that Brexit could make UK holidays more expensive.

Sentiment among the four largest European Union nations (France, Germany, Italy and Spain) is that the UK should stay in the EU, with just under 70% in the Remain camp. In spite of this, respondents from some nations – notably France – believe that leaving the EU could make the UK a safer destination for holidays.

Although almost 75% of the UK’s international visitors come from within the EU, even respondents from further afield (10% of those from Canada and 12% from the US) stated they would be less likely to come to a post-Brexit UK.

Holidays for British tourists in Europe, meanwhile, could become more expensive if the sentiment expressed by some of our neighbours in France and Spain becomes more widespread: 40 per cent of respondents from these countries feel it would be fair to impose higher fees, such as a hiked city tax, on British visitors, if the UK votes Leave on June 23.

UK travellers have their own concerns regarding the impact Brexit could have on the cost of their holiday. Over a quarter (28%) are concerned that withdrawal from the EU could lead to more expensive holidays for them, while 56% are worried that Brexit would reduce the ease and flexibility with which British nationals can currently travel inside the EU.

Other UK tourist concerns include:

  • The price of holiday insurance – 25% are worried that the price of holiday insurance would go up, and 20% worry that their holiday protection cover would be impacted if they were no longer entitled to a European Health Insurance Card
  • The cost of mobile roaming – 24% are concerned that roaming charges will increase if Britain is no longer governed by European Union roaming regulations
  • The impact for UK beaches – 22% worry that UK beaches could become more polluted without strict regulations enforced by the EU

Joel Brandon-Bravo, UK Managing Director of Travelzoo, said: “Our neighbours in Europe clearly don’t want the UK to leave the EU, and the impact of this sentiment could translate into a significant drop in bookings to the UK from the largest European countries. When combined with a potential loss of more than 10 per cent of visitors from North America, as indicated in our research, it’s clear that Brexit could be very bad news for the UK’s domestic tourism industry. Similarly, UK consumers looking to travel abroad also have concerns about Brexit impacting the outbound tourism industry.”

John Fletcher, Pro Vice Chancellor at Bournemouth University (one of the top global academic institutions specialising in travel and tourism), concluded: “Although the impact of Brexit on tourism is a difficult one to predict, given that France, Germany, Italy and Spain make up four of the UK’s top seven tourist-supplying countries – accounting for more than 11 million international visitors annually – it’s likely that the net result of Brexit will be significantly negative for the UK economy. While the figures above reflect only the direct tourism-related economic impacts of voting to leave the EU, if tourist spending from overseas visitors did indeed fall by £4.1 billion per year, this is likely to reduce HMRC revenue by more than £1.1 billion and reduce support for around 63,000 jobs in the UK.

“Even though a UK exit would take some time to complete, especially as renegotiating our revised status with Europe could take five to seven years from start to completion, there will be immediate effects created by this uncertainty.”

Other key findings:

  • The Travelzoo survey of 3,050 British people indicates 46% believe the UK should stay in the EU, while 40% believe it’s time to leave – 14% remain unsure
  • Around a third of Italian (33%), Spanish (33%) and German (30%) travellers, and a quarter of those from France (24%), would be less inclined to travel to the UK in the event of a Leave vote
  • 10% of British people admit they have taken the impact of Brexit into consideration when planning their holiday
  • 12% of Americans and 10% of Canadians say if the UK leaves the EU they would be less likely to travel here. American visitors currently spend more than £3 billion a year in the UK
  • Interestingly for those in favour of an independent UK, 61% said they’d be willing to pay more for their holidays

*About the research

Travelzoo’s survey was conducted using an online questionnaire in the five largest European Union member states by population, and the US and Canada. The questionnaire was completed by 4,950 Travelzoo members across France, Spain, Germany, the US and Canada. For the UK and Italy Travelzoo commissioned independent research with Atomik Research surveying 2,004 consumers in the UK and 1,003 consumers in Italy.

Tourist spending figures calculated by Bournemouth University using data from Travelzoo’s research and figures from VisitBritain’s Inbound Tourism Reports:

About Travelzoo

Travelzoo is a global media commerce company. With more than 28 million members in Asia Pacific, Europe and North America, and 25 offices worldwide, Travelzoo® publishes offers from more than 2,000 travel, entertainment and local companies. Travelzoo’s deal experts review offers to find the best deals and confirm their true value.

Certain statements contained in this press release that are not historical facts may be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934. These forward-looking statements may include, but are not limited to, statements about our plans, objectives, expectations, prospects and intentions, markets in which we participate and other statements contained in this press release that are not historical facts. When used in this press release, the words “expect”, “predict”, “project”, “anticipate”, “believe”, “estimate”, “intend”, “plan”, “seek” and similar expressions are generally intended to identify forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including changes in our plans, objectives, expectations, prospects and intentions and other factors discussed in our filings with the SEC. We cannot guarantee any future levels of activity, performance or achievements. Travelzoo undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release. Travelzoo and Top 20 are registered trademarks of Travelzoo. All other names are trademarks and/or registered trademarks of their respective owners.

Contact information

Laura Higgins, +44-(0)-207-420-0498

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28Pressemelding

Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (, a leading German electronics publication. This press release features multimedia. View the full release here: Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on